Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bruker (BRKR)

Bruker appoints QIAGEN CEO Thierry Bernard to its board, effective April 1, 2026

Neutral Impact 3 of 5 leadership Written later

Bruker Corporation expanded its board to twelve directors and appointed Thierry L. Bernard, who is CEO and Managing Director of QIAGEN N.V., as a director effective April 1, 2026. Bernard will serve until the 2027 Annual Meeting of Stockholders, and QIAGEN has announced he will step down as CEO once a successor is appointed.

Key points

  • Board increased from eleven to twelve directors; Bernard assigned to Class III and serves until the 2027 Annual Meeting
  • Bernard is CEO and Managing Director of QIAGEN N.V. (NYSE: QGEN); QIAGEN announced his CEO transition in November 2025
  • Bruker will file an amended Form 8-K to disclose Bernard's committee assignments once determined

The filing

CompanyBruker (BRKR)
Form8-K, current report
Filed with the SECApr 1, 2026, 7:00 AM ET
Accession number0001193125-26-135660

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.